Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 31;6(1):137.
doi: 10.1038/s41392-021-00559-7.

Longitudinal dynamics of antibody responses in recovered COVID-19 patients

Meng-Li Cheng #  1   2 , Hui-Ying Liu #  3 , Hui Zhao #  2 , Guo-Qing Wang #  1 , Chao Zhou  2 , Jing Zheng  3 , Xiao-Feng Li  2 , Fan Li  4 , Chang-Qing Bai  5 , Cheng-Feng Qin  6
Affiliations
Comment

Longitudinal dynamics of antibody responses in recovered COVID-19 patients

Meng-Li Cheng et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Antibody responses against SARS-CoV-2 spike protein in COVID-19 recovered individuals. IgG (a), IgM (c), and NT50 titers (e) against SARS-CoV-2 S-RBD or S protein of the recovered patients from 5–7 to 34–42 weeks (n = 17). Comparison of the IgG (b), IgM (d), and NT50 titers (f) between mild and severe patients from 5–7 to 34–42 weeks (n = 24). g Correlation analysis of NT50 titers and IgG titers of the recovered patients during 5–42, 5–7, 8–10, 11–13, 14–16, and 34–42 weeks. h Comparison of the PRNT50 titers between mild and severe patients during 5–7 (n = 14) and 14–16 (n = 14) weeks. i Correlation analysis of NT50 titers and PRNT50 titers of the recovered patients during 5–16 weeks (n = 28). Anti-RBD IgG neutralization potency index (NT50/IgG) was calculated (j) and compared between mild and severe patients (k) from 5–7 to 34–42 weeks (n = 24). l Comparison of the anti-RBD IgG neutralization potency index (NT50/IgG) between the patients who treated with corticosteroids or not from 5–7 to 34–42 weeks (n = 24). m The longitudinal dynamics of the anti-RBD IgG neutralization potency index (NT50/IgG) in mild patients who treated with corticosteroids or not (n = 7). n Seroprevalence of the IgG, IgM, NT50, and PRNT50 titers in patients from 5–7 to 34–42 weeks after symptom onset (5–7, n = 14; 8–10, n = 12; 11–13, n = 17; 14–16, n = 10; 34–42, n = 8). n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
See this image and copyright information in PMC

Comment on

  • Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
    Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, Meade P, Mendu DR, Muellers K, Stadlbauer D, Stone K, Strohmeier S, Simon V, Aberg J, Reich DL, Krammer F, Cordon-Cardo C. Wajnberg A, et al. Science. 2020 Dec 4;370(6521):1227-1230. doi: 10.1126/science.abd7728. Epub 2020 Oct 28. Science. 2020. PMID: 33115920 Free PMC article.
  • Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
    Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, Thompson MR, Bradshaw C, Weinkauf CC, Bime C, Erickson HL, Knox K, Bixby B, Parthasarathy S, Chaudhary S, Natt B, Cristan E, El Aini T, Rischard F, Campion J, Chopra M, Insel M, Sam A, Knepler JL, Capaldi AP, Spier CM, Dake MD, Edwards T, Kaplan ME, Scott SJ, Hypes C, Mosier J, Harris DT, LaFleur BJ, Sprissler R, Nikolich-Žugich J, Bhattacharya D. Ripperger TJ, et al. Immunity. 2020 Nov 17;53(5):925-933.e4. doi: 10.1016/j.immuni.2020.10.004. Epub 2020 Oct 14. Immunity. 2020. PMID: 33129373 Free PMC article.

References

    1. Garcia-Beltran WF, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476–488 e411. doi: 10.1016/j.cell.2020.12.015. - DOI - PMC - PubMed
    1. Wajnberg A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227–1230. doi: 10.1126/science.abd7728. - DOI - PMC - PubMed
    1. Slifka MK, Ahmed R. Long-term antibody production is sustained by antibody-secreting cells in the bone marrow following acute viral infection. Ann. N. Y. Acad. Sci. 1996;797:166–176. doi: 10.1111/j.1749-6632.1996.tb52958.x. - DOI - PubMed
    1. Mathew D, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369:eabc8511. doi: 10.1126/science.abc8511. - DOI - PMC - PubMed
    1. Ripperger TJ, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral. Immun. Immun. 2020;53:925–933. - PMC - PubMed